Joint Clinical Trials Office

Tirzepatide’s Role in Postmenopausal HR+ Breast Cancer Survivors

Clinical Trial Details

This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal women with a history of hormone receptor-positive breast cancer and obesity.

The investigators aim to understand whether participants are willing and able to take this medication once weekly via subcutaneous injection for 6 months and whether it may help improve weight and overall health.

There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments and blood tests. A stool sample will be collected, and surveys will also be completed.

Key Eligibility: 

Inclusion criteria:

  1. Biologically female
  2. 18 years of age or older
  3. Obesity as defined by current BMI of greater than or equal to 30 kg/m²
  4. Postmenopausal as defined by one or more of the following,
    -60 years of age or older
    -Amenorrhea for more than 1 year
    -Documented bilateral surgical oophorectomy
    -Chemical menopause with the addition of LHRH agonists at least 12 weeks prior to enrollment, and plan to remain on LHRH agonists throughout the trial

Exclusion criteria: 

  1. Stage IV breast cancer
  2. Concomitant use of CDK inhibitors and/or antiHER2 therapy. (The PI may be consulted regarding enrollment of women receiving other endocrine therapy medications)
  3. Other active malignancy requiring treatment
  4. Enrollment in another investigational clinical trial
  5. Contraindication to tirzepatide
  6. Treatment with a GLP-1 receptor agonist within the last 3 months
  7. Diabetes requiring insulin

Detailed eligibility will be discussed when speaking to the study team.

Return to List

Study contact by location

Upper East Side - Manhattan

Contact(s)

Lynelle Weis
646-962-2423
ljw4002@med.cornell.edu

Primary Investigator(s)

Sarah Schmitz, MD

Protocol ID(s)

Weill Cornell Medicine IRB #:

2506029016

ClinicalTrials.gov:

NCT07257484

Sponsor:

Weill Medical College of Cornell University

Status

Open to Enrollment

Age Group

Adult

Sponsor

  • Weill Cornell Medicine

Disease

Breast Cancer
Weight Loss/Obesity